- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04185857
MRA and ARB Treatment in Screening of Primary Aldosteronism (EMIRA)
Effects of Mineralocorticoid and AT-1 Receptor Antagonism on the Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism Patients (EMIRA Study): Rationale and Design
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary aldosteronism (PA) is a common form of hypertension caused by aldosterone secretion inappropriate for blood pressure (BP) and volume status. It involves over 11% of the patients referred to specialized hypertension centres, about one fifth of those with drug-resistant hypertension and even a large proportion of the hypertensive patients seen in general practice. The only main subtype of PA that can be unambiguously diagnosed based on post-adrenalectomy using a "five corners" approach is aldosterone-producing adenoma (APA).
In patients undergoing screening for PA the current guidelines recommend pharmacological wash-out or, more correctly, switch to antihypertensive therapy not influencing the values of plasma aldosterone concentration (PAC) and direct renin concentration (DRC) and therefore of the aldosterone/renin ratio (ARR). This therapy generally entails a long-acting calcium channel blocker, alone or in combination with an alpha-blocker. However, a significant proportion of hypertensive patients, about one third, require more complex therapies to maintain acceptable BP levels. In addition, a proportion, estimated at around 10% of patients with PA, have hypertension resistant to common antihypertensives, as shown in the PATWAY-2 study. Noteworthy, these patients usually exibit a BP lowering response to mineralocorticoid-receptor antagonists (MRAs).
MRAs act as diuretics and therefore stimulate the renin-angiotensin-aldosterone system (RAAS), which might confound the results of the diagnostic tests, increasing renin and therefore reducing the ARR. This is considered to increase the rate of false negative tests. Moreover, some data suggest that MRA could inhibit the synthesis of aldosterone. However, this remains contentious as there are no prospective studies in this regard. Therefore, the use of MRAs, which can effectively control BP and hypokalemia during the PA screening is generally discouraged, despite the lack of solid prospective studies in this regard.
The stimulation of SRAA, if it actually occurs in a patient with PA, could be controlled, or prevented, by the use of an angiotensin AT-1 receptor blocker.
Therefore, the investigators set out a prospective observational study aimed at investigating, with a within-patient comparison, the values of PAC, DRC, ARR, serum potassium, in addition to blood pressure, in patients unambigously diagnosed with PA, who underwent screening and subtyping in washout from confounding treatments according to the current guidelines, with the values produced by treatment with MRA (canrenone) given alone or in combination with an angiotensin AT-1 receptor blocker (olmesartan).
Methods:
The investigators will prospectively recruit consecutive PA patients which have been previously studied in washout from confounding treatments (first basal evaluation) and will be subtyped by adrenal vein sampling (AVS) in the Clinica dell'Ipertensione Arteriosa, University of Padova, Italy (second basal evaluation). Inclusion criteria: patients between the ages of 18 and 75, diagnosed with APA according with the guidelines, which will give written informed consent. The exclusion criteria comprise the refusal to participate in the study of the history of intolerance or allergy to canrenone or ARBs.
Patients will be treated with canrenone 50-100 mg orally for 1 month followed by canrenone plus olmesartan 10 or 20 mg for another month. At the end of each month they will undergo a clinical and biochemical reevaluation to investigate the effects of both treatments and compared with the ARR values observed during washout (i.e. during the first and second basal evaluations).
Study design:
After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After one and tho weeks the dose will be doubled if necessary to control BP and serum potassium. After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations.
After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension.
At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone.
This protocol is commonly used in the Center of Reference - UOSD Hypertension for the optimal preparation of patients with PA for the eventual intervention of laparoscopic adrenalectomy.
Primary endpoint:
This is a prospective, within-patient, observational study aiming at comparing, in patients with PA, the values of PAC, DRC and ARR assessed in wash-out (or in treatment with CCBs and or alfa-blockers) with the values observed after 1 month treatment with canrenone 50 or 100 mg o.d. and after another month treatment with canrenone 50 or 100 mg o.d. plus olmesartan 10 mg or 20 mg o.d.
Sample size calculation and statistical analysis A statistical power to detect any intra-patient difference of ormonal concentrations will be reached considering 40 patients.
The analysis of the data will be performed initially globally (i.e. on the entire cohort) and subsequently conducted separately: in patients with APA where the diagnosis will be confirmed at the adrenalectomy and biochemical follow-up one month after surgery, and in patients with PA not lateralized where the one month follow up will be performed.
Expected Results. The investigators expect to conclusively determine if and how MRA alone or combined with an ARB at doses that control BP and hypokalemia, affect plasma concentration of PAC and DRC and therefore the ARR.
If the results of this study will not show a confounding effect of one or the other treatment, this study could open the way to perform the screening tests for PA without the need to suspend these treatments and therefore with the possibility of minimizing the risks due to the reduction of therapy antihypertensive in hypertensive patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Padova, Italy
- Department of Medicine - DIMED, University of Padova, Italy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age 18 - 75 years;
- diagnosis of Aldosterone Producing Adenoma (APA);
- written informed consent.
Exclusion Criteria:
- refusal to participate to the study;
- history of intolerance or allergy to canrenone or ARB.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with primary aldosteronism (PA)
After two biochemical and clinical evaluations under baseline conditions PA patients will be treated with canrenone 50-100 mg orally once a day. After one month of such therapy they will undergo the a clinical and biochemical evaluation (FW1). After, they will continue with a combination therapy with canrenone, plus olmesartan starting with 10 mg a day for oral administration, a dose that can be doubled, if necessary, to achieve normotension. At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2). |
After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day.
After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension. At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aldosterone to renin ratio (ARR)
Time Frame: one month
|
ARR measured as ng/mIU after treatment with canrenone, or olmesartan on top of canrenone
|
one month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum potassium levels
Time Frame: one month
|
Serum potassium measured as mmol/L after treatment with canrenone, or olmesartan on top of canrenone
|
one month
|
Blood pressure
Time Frame: one month
|
Blood pressure measured as mmol/L after treatment with canrenone, or olmesartan on top of canrenone
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gian Paolo Rossi, University of Padova
Publications and helpful links
General Publications
- Rossitto G, Cesari M, Ceolotto G, Maiolino G, Seccia TM, Rossi GP. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design. J Hum Hypertens. 2019 Feb;33(2):167-171. doi: 10.1038/s41371-018-0139-x. Epub 2018 Dec 5.
- Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300. doi: 10.1016/j.jacc.2006.07.059. Epub 2006 Nov 13.
- Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008 Jun 7;371(9628):1921-6. doi: 10.1016/S0140-6736(08)60834-X. Erratum In: Lancet. 2008 Dec 13;372(9655):2022.
- Seccia TM, Caroccia B, Gomez-Sanchez EP, Gomez-Sanchez CE, Rossi GP. The Biology of Normal Zona Glomerulosa and Aldosterone-Producing Adenoma: Pathological Implications. Endocr Rev. 2018 Dec 1;39(6):1029-1056. doi: 10.1210/er.2018-00060.
- Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Adrenocortical Hyperfunction
- Adrenal Gland Diseases
- Adenoma
- Hyperaldosteronism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Olmesartan
- Canrenone
Other Study ID Numbers
- EMIRA-64140
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Aldosteronism Due to Aldosterone Producing Adenoma
-
University Hospital PadovaUnknownPrimary Aldosteronism Due to Aldosterone Producing Adenoma
-
Changi General HospitalKhoo Teck Puat Hospital; Singapore General Hospital; Tan Tock Seng Hospital; National... and other collaboratorsCompletedPrimary Aldosteronism | Primary Aldosteronism Due to Aldosterone Producing AdenomaSingapore
-
UMC UtrechtM.D. Anderson Cancer Center; University Health Network, Toronto; University of... and other collaboratorsCompletedPrimary Aldosteronism | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Conn AdenomaUnited States, Netherlands, Australia, Canada, Italy
-
Henan Institute of Cardiovascular EpidemiologyCompletedPrimary Aldosteronism Due to Aldosterone Producing AdenomaChina
-
Changi General HospitalKhoo Teck Puat Hospital; Singapore General Hospital; Tan Tock Seng Hospital; Sengkang... and other collaboratorsRecruitingPrimary Aldosteronism | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Adrenal TumorsSingapore
-
Uppsala UniversityBritish Medical Research Council; Uppsala University HospitalCompletedAdrenocortical Carcinoma | Adrenal Cushing Syndrome | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Nodular Hyperplasia | Non-Secretory Adrenal AdenomaSweden
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingPrimary Aldosteronism | Aldosterone-Producing Adenoma | Idiopathic HyperaldosteronismChina
-
Haukeland University HospitalRecruitingPrimary Aldosteronism | Aldosterone-Producing AdenomaNorway
-
Changi General HospitalCompletedPrimary Aldosteronism | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)Singapore
-
University of Turin, ItalyCompletedPrimary Aldosteronism | Primary Aldosteronism Due to Aldosterone Producing Adenoma | Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)Italy
Clinical Trials on canrenone 50-100 mg orally once a day
-
Shanghai Fosun Pharmaceutical Industrial Development...RecruitingNeurofibromatosis 1 | NF1 | Plexiform NeurofibromaChina
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedAtopic DermatitisUnited States
-
Chinese PLA General HospitalCompletedStem Cell Transplant Complications | aGVHDChina
-
University of PaviaCompletedEssential Hypertension
-
HaEmek Medical Center, IsraelUnknownDistal UreterolithiasisIsrael
-
Samsung Medical CenterHanmi Pharmaceutical co., ltd.Active, not recruitingCoronary Artery DiseaseKorea, Republic of
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
Fundacion Clinic per a la Recerca BiomédicaWithdrawnLiver Transplantation | Hepatitis C
-
Merck Sharp & Dohme LLCTerminated